Treatment Approach for Periodic Limb Movement Disorder
The primary issue here is not sleep apnea (AHI of 8 is borderline and oxygen saturation is adequate), but rather the elevated periodic limb movement index of 37/h with repetitive leg movements during wakefulness, which requires evaluation for Periodic Limb Movement Disorder (PLMD) versus Restless Legs Syndrome (RLS).
Critical First Step: Distinguish PLMD from RLS
Before initiating any treatment, you must determine whether this patient has:
RLS: Characterized by an urge to move the legs when immobile, associated with dysesthesias, relieved by movement, and worse in the evening/night. This is a clinical diagnosis based on history, not polysomnography findings 1.
PLMD: Diagnosed when PLMS are >15 events/h in adults AND there is clinically significant sleep disturbance or daytime dysfunction that is not better explained by another disorder 1. Critically, PLMD requires absence of RLS and exclusion of other sleep disorders associated with high PLMS rates 1.
The presence of "repetitive leg movements during wakefulness" strongly suggests RLS rather than PLMD, as these wakeful movements are characteristic of RLS 1.
If This Is RLS (Most Likely Scenario)
First-Line Pharmacotherapy
According to the 2025 AASM guidelines, the strongest recommendations for RLS treatment are 1:
- Gabapentin enacarbil (strong recommendation, moderate certainty)
- Gabapentin (strong recommendation, moderate certainty)
- Pregabalin (strong recommendation, moderate certainty)
These alpha-2 delta calcium channel ligands are preferred over dopaminergic agents, which are now recommended against for standard use due to augmentation risk with long-term therapy 1.
Iron Evaluation and Supplementation
Before or concurrent with pharmacotherapy:
- Check ferritin and transferrin saturation 1
- If ferritin <200 ng/mL and transferrin saturation <20%:
Avoid Dopamine Agonists as First-Line
The 2025 guidelines specifically suggest against standard use of 1:
- Pramipexole
- Ropinirole
- Transdermal rotigotine
- Levodopa
These may only be considered in patients who prioritize short-term symptom reduction over long-term augmentation risk 1.
If This Is True PLMD (Less Likely)
If the patient has no RLS symptoms (no urge to move, no dysesthesias, no relief with movement, no circadian pattern), and the PLMS are causing the sleep disturbance:
- The 2025 AASM guidelines provide limited specific recommendations for PLMD
- They suggest against valproic acid (conditional recommendation) 1
- They suggest against triazolam (conditional recommendation) 1
- Treatment typically follows similar principles to RLS with gabapentinoids, though evidence is weaker 2
Regarding the Borderline Sleep Apnea
The AHI of 8 is just above the threshold for mild OSA (AHI ≥5), but:
- No snoring reported
- Oxygen saturation nadir of 86% is acceptable
- The elevated PLMI may be the primary driver of any sleep disturbance
Do not initiate CPAP therapy based solely on this borderline AHI without clear OSA symptoms. However, be aware that:
- CPAP can sometimes improve RLS symptoms in patients with comorbid OSA 3
- CPAP can also cause "CPAP-emergent" PLMS in some patients 4
- The relationship between OSA and PLMS is complex and bidirectional 5
Common Pitfalls to Avoid
Do not treat PLMS on polysomnography alone without establishing clinical significance and excluding RLS 1
Do not start dopamine agonists as first-line therapy despite their historical use—the 2025 guidelines represent a major shift away from these agents due to augmentation concerns 1
Do not overlook iron deficiency—checking iron parameters is essential before or concurrent with pharmacotherapy 1
Do not assume CPAP will resolve the leg movements—while it may help in some cases, it can also worsen PLMS in others 4
Do not diagnose PLMD if RLS symptoms are present—PLMD is a diagnosis of exclusion 1